A Phase 1 Study in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of
prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or
metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell
cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three
different groups of participants; those with squamous cell cancer of the head and neck that
has recurred or spread to other parts of the body, those with squamous non-small cell lung
cancer that has recurred or spread, and those with squamous cell cancer of the anus that is
not curable by existing therapy.